Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation
Sponsor: Columbia University
This PHASE3 trial investigates Prostate Cancer and is currently completed. Columbia University leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Holy Cross Hospital, Fort Lauderdale
- Louisiana State University Health Sciences Center in New Orleans
- National Cancer Institute (NCI)
- United States Naval Medical Center, Portsmouth
- University of Minnesota
- University of Pittsburgh
- University of Washington
- Wayne State University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bethesda, United States
- • Detroit, United States
- • Fort Lauderdale, United States
- • Minneapolis, United States
- • New Orleans, United States
- • New York, United States
- • Pittsburgh, United States
- • Portsmouth, United States
- • Seattle, United States